Clinical Trials in Varaždin, Croatia
9 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled157 locationsNCT07011732
Recruiting
Phase 3
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Diabetes MellitusObesityOverweight
Novo Nordisk A/S630 enrolled74 locationsNCT07533175
Recruiting
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Alzheimer DiseaseAgitation
Bristol-Myers Squibb600 enrolled255 locationsNCT06937229
Recruiting
Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Diabetes Mellitus, Type 2
Novo Nordisk A/S270 enrolled63 locationsNCT07415954
Recruiting
Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Heart FailureAcute Heart Failure
Colorado Prevention Center5,200 enrolled299 locationsNCT06008197
Recruiting
Prognostic Value of SII and SIRI in Obesity-Related Metabolic Complications
Metabolic SyndromeInflammationOverweight and Obesity
University of Rijeka200 enrolled1 locationNCT07431593
Recruiting
Phase 3
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Sandoz175 enrolled41 locationsNCT06847724
Recruiting
Phase 3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Ischemic Stroke; Ischemic Attack, Transient
Janssen Research & Development, LLC15,000 enrolled880 locationsNCT05702034
Recruiting
Phase 3
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.360 enrolled42 locationsNCT07211633